Zobrazeno 1 - 10
of 14
pro vyhledávání: '"59"'
Publikováno v:
Cancer Epidemiol Biomarkers Prev
Background: U.S. breast cancer incidence has been changing, as have distributions of risk factors, including body mass index (BMI), age at menarche, age at first live birth, and number of live births. Methods: Using data for U.S. women from large nat
Autor:
José Bines, Joseph Gligorov, Emilio Alba, Giorgio Mustacchi, S de Ducla, P Button, Dinesh Chandra Doval, Paulo Cortes
Publikováno v:
Cancer Research. 77:P5-15
BACKGROUND The open-label randomized phase III IMELDA trial demonstrated that adding CAP to maintenance BEV until disease progression after initial BEV + docetaxel (DOC) provides statistically significant and clinically meaningful improvements in bot
Autor:
D. Neoh, K. Taylor, Farshad Foroudi, D. Grinsell, C. Foley, S.W. Loh, M. Law, M. Cheng, M. Cokelek, Michael Chao, V. Yu, A. Hyett, C. Baker, D. Stoney, N. Zantuck, M. Guerrieri, M. Chipman, D. Lim Joon, E. Bevington, G. Chew, S. Jassal
Publikováno v:
Cancer Research. 78:P2-11
Introduction Delayed breast reconstructions are preferred if post mastectomy radiotherapy is indicated due to lower complication rates compared to immediate permanent implant or autologous reconstructions (AR) but cosmetic outcomes are inferior. Radi
Autor:
D-C Yeh, W. Wu, Wei Li, H. Iwata, C. Goessl, S-A Im, L-M Tseng, Mark E. Robson, Y-H Park, Noriyuki Masuda, Sarah Runswick, B H Xu, Quchang Ouyang, Jung Ho Sohn
Publikováno v:
Cancer Research. 78:P5-21
Background In the Phase III OlympiAD trial (NCT02000622, D0819C00003), olaparib (Lynparza™) showed a significant progression-free survival (PFS) improvement compared with chemotherapy treatment of physician's choice (TPC) in patients (pts) with met
Autor:
Ke Zhang, Noriyuki Masuda, S. Verma, N. Turner, S. L. Moulder, C Huang-Bartlett, DJ Slamon, W Sun, Richard S. Finn, S Kim, HS Rugo, Nadia Harbeck, Anil A. Joy, Patrick Schnell, Y-H Im
Publikováno v:
Cancer Research. 77:P4-22
Background: At least 40% of breast cancers are diagnosed in women ≥65 y old and most are hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-). Palbociclib (PAL) is an oral, small-molecule inhibitor of cyclin-depen
Autor:
Beverly Moy, Dejan Juric, Borger, Priscilla Kaliopi Brastianos, Dora Dias-Santagata, Donna M. Fitzgerald, SJ Isakoff, Kevin S. Oh, Ha Shih, Anthony J. Iafrate, L. Henderson, Aditya Bardia
Publikováno v:
Cancer Research. 77:P1-12
Introduction: Historically, brain metastases are considered to be uncommon in HR+/HER2- breast cancer compared to triple-negative or HER2+ breast cancer. However, improved systemic therapy and prolonged overall survival in patients with metastatic HR
Autor:
Wendy Y. Chen, Carla M. Prado, Adrienne Castillo, Patrick T. Bradshaw, Erin Weltzien, Candyce H. Kroenke, Bette J. Caan, Elizabeth M. Cespedes Feliciano
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 26:44-50
Background: Achieving a healthy weight is recommended for all breast cancer survivors. Previous research on postdiagnosis weight change and mortality had conflicting results. Methods: We examined whether change in body weight in the 18 months followi
Autor:
P García, J. Florián, P. Zamora, Sonia Servitja, A. Velasco, M. A. Seguí, E Artime, L. De Paz, J de la Haba, Eduardo Martínez, Jose Manuel Perez Garcia, Ana Santaballa, J. Rodríguez-Villanueva, I Chacón, Y Plata, I Garau
Publikováno v:
Cancer Research. 76:P3-07
BACKGROUND: Currently available therapeutic armamentarium for locally advanced and/or metastatic breast cancer (LA/MBC) allows an increasing tailored approach for each of the major tumor immunophenotypes. Nevertheless, there is scarce information abo
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 25:28-35
Background: Herpes zoster (HZ) arises in older people due to age-related decline in immunity. We assessed whether HZ, as a marker of immune suppression, is associated with increased cancer risk. Methods: We conducted a case–control study in U.S. ad
Autor:
C Huang Bartlett, Kathy D. Miller, HJ Burstein, Maria Koehler, HS Rugo, Therese M. Mulvey, S Come, Erica L. Mayer, William H. Barry, Adrienne G. Waks, EP Winer, H Guo, AM DeMichele, Bryan P. Schneider
Publikováno v:
Cancer Research. 78:PD5-06
Background: The CDK4/6 inhibitor palbociclib (P) combined with endocrine therapy (ET) prolongs progression-free survival in previously untreated and treated hormone receptor positive/HER2 negative (HR+/HER2-) metastatic breast cancer (MBC). The most